Meeting report on 8th International Symposium on Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy.
The platinum-based drugs, cisplatin and carboplatin, represent major agents in the chemotherapeutic treatment of a variety of types of cancer. Novel, "third-generation" agents aimed at broadening the clinical activity of this class of drug are currently undergoing clinical evaluation. These include oxaliplatin, ZD0473 and BBR3464. Clinical trials and preclinical studies are also being conducted with liposomal (SPI-077 and L-NDDP) and polymeric platinum complexes (linked to HPMA or albumin). Combination studies of cisplatin/carboplatin with other anticancer drugs such as gemcitabine and UCN-01 (7-hydroxystaurosporine) and agents designed to reduce platinum drug toxicities (e.g., BNP-7787, DIMESNA) are ongoing. Preclinically, there is interest in trans platinum complexes, terpyridine platinum(II) complexes and other metal-containing agents (ruthenium and gold).
Kelland
L R
LR
CRC Centre for Cancer Therapeutics, Institute of Cancer Research, Sutton, Surrey, UK. lloyd@icr.ac.uk
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004247:DNA / Q000187:drug effects / Q000378:metabolism; D019008:Drug Resistance, Neoplasm; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D009944:Organoplatinum Compounds / Q000494:pharmacology; D017671:Platinum Compounds / Q000138:chemical synthesis / Q000494:pharmacology* / Q000627:therapeutic use; D011506:Proteins / Q000187:drug effects / Q000378:metabolism
D009944:Organoplatinum Compounds; D017671:Platinum Compounds; D011506:Proteins; D004247:DNA; C114062:BBR 3464